$RARE — BUY 📊 | 6 MONTHS THESIS

$RARE — BUY 📊 | 6 MONTHS THESIS 🎯 Q2 2026 | EPS $-1.10 vs $-1.10 ➖ 💡 Consensus focuses on the EPS miss and ongoing losses, neglecting the transformative potential of the gene therapy pipeline. Our variant view is that upcoming data readouts have a higher probability of success than reflected in the current price, and Crysvita growth remains robust. 📉 Reward/risk: 2.36:1 🏢 Business Quality: 6/10 - Stable revenue from approved products but unprofitable; high-risk, high-reward pipeline typical of biotech. 📊 Valuation: Fair - At ~$27.44, EV/Sales of ~4.6x is in line with unprofitable rare disease peers, but probability-adjusted DCF of the pipeline suggests upside to... 🔮 Catalyst: Phase 3 data for DTX401 (GSDIa gene therapy) readout 💰 Entry: $27.44, stop $20.0, target $45.0 📊 Our read: BUY. Full analysis → https://stockduty.xyz/s/RARE0620

🎯 Q2 2026 | EPS $-1.10 vs $-1.10 ➖